Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
Food and Drug Administration
The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development. Awards range from $650,000 to $900,000.
Deadline
Not published. Check the funder's page.
Who can apply
Open to: Public housing authorities/Indian housing authorities; City or township governments; Private institutions of higher education; Independent school districts; For profit organizations other than small businesses; County governments; State governments; Special district governments.
Sources
Grants.gov. Last updated 2026-10-26.
Always confirm eligibility and deadlines on the funder's own page before applying.